BUDZ Quote, Financials, Valuation and Earnings

Cencora has a net margin of -- compared to Weed's net margin of 0.6%. Weed's return on equity of -- beat Cencora's return on equity of 155.22%.

Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Cencora has an analysts' consensus of $287.49 which suggests that it could grow by 1.11%. Given that Cencora has higher upside potential than Weed, analysts believe Cencora is more attractive than Weed.

Weed has a beta of 0.658, which suggesting that the stock is 34.206% less volatile than S&P 500. In comparison Cencora has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.294%.

Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cencora offers a yield of 0.75% to investors and pays a quarterly dividend of $0.55 per share. Weed pays -- of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Weed quarterly revenues are --, which are smaller than Cencora quarterly revenues of $81.5B. Weed's net income of -$95.9K is lower than Cencora's net income of $488.6M. Notably, Weed's price-to-earnings ratio is 180.00x while Cencora's PE ratio is 40.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.19x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

Henry Schein has a net margin of -- compared to Weed's net margin of 2.95%. Weed's return on equity of -- beat Henry Schein's return on equity of 7.8%.

Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Henry Schein has an analysts' consensus of $77.85 which suggests that it could grow by 20.77%. Given that Henry Schein has higher upside potential than Weed, analysts believe Henry Schein is more attractive than Weed.

Weed has a beta of 0.658, which suggesting that the stock is 34.206% less volatile than S&P 500. In comparison Henry Schein has a beta of 0.844, suggesting its less volatile than the S&P 500 by 15.587%.

Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Henry Schein offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Weed pays -- of its earnings as a dividend. Henry Schein pays out -- of its earnings as a dividend.

Weed quarterly revenues are --, which are smaller than Henry Schein quarterly revenues of $3.2B. Weed's net income of -$95.9K is lower than Henry Schein's net income of $94M. Notably, Weed's price-to-earnings ratio is 180.00x while Henry Schein's PE ratio is 21.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.65x for Henry Schein. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of -- compared to Weed's net margin of 0.92%. Weed's return on equity of -- beat McKesson's return on equity of --.

Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand McKesson has an analysts' consensus of $693.18 which suggests that it could grow by 0.55%. Given that McKesson has higher upside potential than Weed, analysts believe McKesson is more attractive than Weed.

Weed has a beta of 0.658, which suggesting that the stock is 34.206% less volatile than S&P 500. In comparison McKesson has a beta of 0.494, suggesting its less volatile than the S&P 500 by 50.561%.

Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. McKesson offers a yield of 0.4% to investors and pays a quarterly dividend of $0.71 per share. Weed pays -- of its earnings as a dividend. McKesson pays out 10.46% of its earnings as a dividend. McKesson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Weed quarterly revenues are --, which are smaller than McKesson quarterly revenues of $95.3B. Weed's net income of -$95.9K is lower than McKesson's net income of $879M. Notably, Weed's price-to-earnings ratio is 180.00x while McKesson's PE ratio is 31.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.26x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

Pineapple has a net margin of -- compared to Weed's net margin of --. Weed's return on equity of -- beat Pineapple's return on equity of --.

Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Weed has higher upside potential than Pineapple, analysts believe Weed is more attractive than Pineapple.

Weed has a beta of 0.658, which suggesting that the stock is 34.206% less volatile than S&P 500. In comparison Pineapple has a beta of 32.190, suggesting its more volatile than the S&P 500 by 3119.041%.

Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Weed pays -- of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend.

Weed quarterly revenues are --, which are smaller than Pineapple quarterly revenues of --. Weed's net income of -$95.9K is higher than Pineapple's net income of --. Notably, Weed's price-to-earnings ratio is 180.00x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 32.44x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.